- Home
- CLLS vs BWG Comparison
CLLS vs BWG Comparison
Compare CLLS & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- BWG
- Stock Information
- Founded
- CLLS 1999
- BWG 2012
- Country
- CLLS France
- BWG United States
- Employees
- CLLS N/A
- BWG N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- BWG Finance/Investors Services
- Sector
- CLLS Health Care
- BWG Finance
- Exchange
- CLLS Nasdaq
- BWG Nasdaq
- Market Cap
- CLLS 143.4M
- BWG 136.3M
- IPO Year
- CLLS 2007
- BWG N/A
- Fundamental
- Price
- CLLS $1.58
- BWG $8.36
- Analyst Decision
- CLLS Buy
- BWG
- Analyst Count
- CLLS 1
- BWG 0
- Target Price
- CLLS $4.00
- BWG N/A
- AVG Volume (30 Days)
- CLLS 50.1K
- BWG 53.8K
- Earning Date
- CLLS 08-05-2025
- BWG 01-01-0001
- Dividend Yield
- CLLS N/A
- BWG 11.37%
- EPS Growth
- CLLS N/A
- BWG N/A
- EPS
- CLLS N/A
- BWG N/A
- Revenue
- CLLS $54,747,000.00
- BWG N/A
- Revenue This Year
- CLLS $48.52
- BWG N/A
- Revenue Next Year
- CLLS $5.17
- BWG N/A
- P/E Ratio
- CLLS N/A
- BWG N/A
- Revenue Growth
- CLLS 351.26
- BWG N/A
- 52 Week Low
- CLLS $1.10
- BWG $6.86
- 52 Week High
- CLLS $2.43
- BWG $8.65
- Technical
- Relative Strength Index (RSI)
- CLLS 60.33
- BWG 66.53
- Support Level
- CLLS $1.41
- BWG $8.08
- Resistance Level
- CLLS $1.60
- BWG $8.17
- Average True Range (ATR)
- CLLS 0.09
- BWG 0.08
- MACD
- CLLS 0.02
- BWG 0.02
- Stochastic Oscillator
- CLLS 83.52
- BWG 92.86
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About BWG BrandywineGLOBAL Global Income Opportunities Fund Inc.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.